Targeted therapy

Question 1

What is bevacizumab?

Answer 1

Humanized monoclonal antibody to VEGF

Question 2

What is the MOA of bevacizumab?

Answer 2

Binds to VEGF and prevents VEGFR activation

Question 3

Special administrations for bevacizumab?

Answer 3

• IV over 90 minutes for first course; then 60 and 30 minutes
• 15 mg/kg q 3 weeks (some 7.5 mg/kg); 10 mg/kg q 2 weeks

Question 4

Toxicities of bevacizumab?

Answer 4

• Hypertension
• Proteinuria
• Impaired wound healing (up to 7% fistula rate in GOG 240)
• Thromboembolic disease
• GI perforation (1-2%)
• Reversible posterior leukoencephalopathy syndrome (RPLS) (<1%)